TREA

97042228 - MORPHOSYS

Follow

Information

  • Trademark
  • 97042228
  • Serial Number
    97042228
  • Registration Number
    7071326
  • Filing Date
    September 23, 2021
    3 years ago
  • Registration Date
    June 06, 2023
    a year ago
  • Transaction Date
    June 06, 2023
    a year ago
  • Status Date
    June 06, 2023
    a year ago
  • Published for Opposition Date
    March 21, 2023
    a year ago
  • Location Date
    June 06, 2023
    a year ago
  • Status Code
    700
  • Current Location
    PUBLICATION AND ISSUE SECTION
    Employee Name
    WANG, YUAN YUAN
  • Attorney Docket Number
    114353.00147
    Attorney Name
    Michael J. Leonard
    Law Office Assigned Location Code
    L90
  • Owners
Information
Mark Drawing Code
4000
Mark Identification
MORPHOSYS
Case File Statements
  • GS0051: pharmaceutical preparations for the treatment of diseases that involve dysregulation of epigenetic pathways; pharmaceutical preparations for epigenetic modulators as therapeutics; pharmaceuticals comprising small molecules for the treatment and prevention of metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer's, sepsis, and restenosis; small molecule compounds for use as drug delivery agents in pharmaceuticals; small molecule compounds being pharmaceuticals for the treatment and prevention of diseases and disorders, namely, metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer's, sepsis, and restenosis in humans; small molecule pharmaceuticals for the treatment of diseases and conditions, namely, metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer's, sepsis, and restenosis; Pharmaceuticals and pharmaceutical preparations for human use for the treatment and prevention of diseases and disorders, namely, metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer's, sepsis, and restenosis; antibodies sold as a component ingredient of pharmaceuticals for the treatment of metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer's, sepsis, and restenosis; diagnostic preparations for medical purposes; biological substances for human medical diagnostics and analysis for the treatment of metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer's, sepsis, and restenosis; Clinical medical reagents; Biological preparations for medical purposes, namely, for the treatment of metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer's, sepsis, and restenosis; pharmaceutical and veterinary preparations, agents and substances for the treatment of metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer's, sepsis, and restenosis
  • GS0011: reagents for scientific and medical research for use in the research and production of small molecule pharmaceuticals; active pharmaceutical ingredients, namely, antibodies, proteins and small molecules for use in the manufacture of pharmaceuticals, biopharmaceuticals, vaccines, and finished drug products; antibodies for use in the manufacture of active ingredients of pharmaceuticals and vaccines
  • GS0421: Pharmaceutical research and development of pharmaceutical preparations, medicines and vaccines; providing medical and scientific research information; Scientific research in the nature of conducting clinical trials for others; scientific and technological services, namely, scientific research, analysis, and testing services in the fields of analytical chemistry, biochemistry, medicinal chemistry, drug development, biotechnology, microbiology and molecular biology; research and design services, namely, research and development in the field of antibodies and clinical research in connection with the treatment and prevention of metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer's, sepsis, and restenosis
Case File Event Statements
  • 6/6/2023 - a year ago
    24 - NOTICE OF REGISTRATION CONFIRMATION EMAILED Type: NRCC
  • 6/6/2023 - a year ago
    23 - REGISTERED-PRINCIPAL REGISTER Type: R.PR
  • 3/21/2023 - a year ago
    22 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 3/21/2023 - a year ago
    21 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 3/1/2023 - a year ago
    20 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 2/13/2023 - a year ago
    19 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 2/10/2023 - a year ago
    18 - EXAMINER'S AMENDMENT ENTERED Type: XAEC
  • 2/10/2023 - a year ago
    17 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN
  • 2/10/2023 - a year ago
    16 - EXAMINERS AMENDMENT E-MAILED Type: GNEA
  • 2/10/2023 - a year ago
    15 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA
  • 2/1/2023 - 2 years ago
    14 - EXAMINER'S AMENDMENT ENTERED Type: XAEC
  • 2/1/2023 - 2 years ago
    13 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN
  • 2/1/2023 - 2 years ago
    12 - EXAMINERS AMENDMENT E-MAILED Type: GNEA
  • 2/1/2023 - 2 years ago
    11 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA
  • 1/10/2023 - 2 years ago
    10 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 1/10/2023 - 2 years ago
    9 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 1/9/2023 - 2 years ago
    8 - ASSIGNED TO LIE Type: ALIE
  • 11/11/2022 - 2 years ago
    7 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 6/27/2022 - 2 years ago
    6 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 6/27/2022 - 2 years ago
    5 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 6/27/2022 - 2 years ago
    4 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 6/24/2022 - 2 years ago
    3 - ASSIGNED TO EXAMINER Type: DOCK
  • 10/25/2021 - 3 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 9/27/2021 - 3 years ago
    1 - NEW APPLICATION ENTERED Type: NWAP